New-Onset Pediatric Crohn's Disease With Growth Failure: Choosing and Executing Exclusive Enteral Nutrition
An 11-year-old boy is diagnosed with moderate-to-severe ileocolonic Crohn's disease after a 5-month history of abdominal pain, four to six loose stools daily, and fatigue. Height 138 cm (25th percentile), weight 31.0 kg (5th percentile), down from 34 kg four months ago. He has not started puberty. Labs: hemoglobin 10.2 g/dL, CRP 28 mg/L, albumin 3.1 g/dL, ferritin 12 ng/mL, 25-hydroxyvitamin D 22 ng/mL, fecal calprotectin 780 mcg/g. His pediatric gastroenterologist offers either oral prednisolone or exclusive enteral nutrition (EEN). The family is hesitant about steroids because a cousin had 'mood problems' and weight gain on them; the mother asks whether a specific carbohydrate diet or a liquid formula 'counts as treatment'. He attends school full-time and plays basketball; the family has two working parents.
1. Compare EEN and corticosteroids for this boy, weighing mucosal healing, growth, and practicality.
Read the worked answer
Efficacy. In pediatric Crohn's induction, EEN achieves clinical remission rates comparable to corticosteroids (roughly 70–80% in trials) but is superior for mucosal healing and for restoring lean mass and linear growth. Corticosteroids suppress inflammation quickly but do not heal mucosa reliably, do not improve growth, and cause growth velocity suppression, mood lability, acne, and bone loss - the exact concerns the family raised. For a prepubertal boy who has lost 3 kg and whose height centile is already below his genetic potential, the growth argument is decisive: guidelines from pediatric GI societies position EEN as a first-line induction option in children, particularly with growth failure.
Trade-offs to state honestly. EEN requires 6–8 weeks of 100% formula, which affects school and social participation and demands high family buy-in; adherence failure is the main reason it underperforms. It also has no maintenance benefit - relapse follows food reintroduction unless a maintenance agent is started. Steroids are easier to administer and have faster symptom relief, which matters if he is clinically deteriorating. There is no evidence a specific carbohydrate diet induces remission; exclusion diets are not equivalent to EEN and risk worsening his already compromised intake.
Shared decision. Present both with numbers, offer a planned NG tube, and agree on a review point at 2 weeks with objective markers so a failing EEN trial converts to another agent rather than drifting.
2. Design the EEN prescription: formula, target volume, route, ramp-up, duration, and monitoring.
Read the worked answer
Targets. For catch-up in an 11-year-old at 31 kg, aim 100–120 kcal/kg/day, i.e. ~1,900–2,200 kcal/day, with protein 2–2.5 g/kg/day (~65–75 g/day). His estimated maintenance is lower, so this deliberately provides a surplus to rebuild lean mass.
Formula and route. A standard polymeric pediatric formula (1.0 kcal/mL) is appropriate; there is no proven advantage of elemental formulas in uncomplicated Crohn's, and polymeric is cheaper and more palatable for the sips allowed. If volume tolerance is an issue, a 1.5 kcal/mL formula reduces the load: e.g., ~1,400 mL/day of 1.5 kcal/mL provides ~2,100 kcal, delivered nocturnally by NG tube at ~115–120 mL/h over 12 hours, allowing daytime water sips, sugar-free gum, and normal school attendance.
Ramp-up. Start at half the target rate on night 1 and advance over 2–3 nights to reduce dumping and refeeding risk. Check phosphate, potassium, magnesium, and glucose at baseline and 48–72 hours; his refeeding risk is low-to-moderate given a 3 kg loss, so do not skip this.
Duration and monitoring. 6–8 weeks of exclusive formula, then structured reintroduction of one food every 2–3 days over 2–3 weeks while tapering formula to a partial volume. Monitor weight twice weekly during ramp-up then weekly, CRP and albumin at 2 and 8 weeks, fecal calprotectin at 8 weeks, and growth every 3 months. Continue vitamin D, replace iron once inflammation is controlled (ferritin 12 with active inflammation underestimates deficiency), and reassess puberty staging at 3 months.
3. The mother asks whether the formula 'really counts as treatment' and whether a specific carbohydrate diet would be safer. How do you respond?
Read the worked answer
Direct answer. Yes - the formula is the treatment in EEN. Remission is achieved by delivering complete nutrition exclusively, removing dietary antigen load and altering the microbiome, not by any special property of the liquid itself. That is why 'just adding a supplement drink' to a normal diet is not equivalent and has much weaker evidence (partial enteral nutrition is a maintenance strategy at best).
Specific carbohydrate diet. Acknowledge that families read about it and that small uncontrolled studies exist, but state plainly that there is no randomized evidence it induces remission in children, while there is clear evidence of nutritional risk with a restrictive diet in a boy who has already lost 3 kg and has low ferritin and vitamin D. Framing it as 'we can revisit this after induction if you want to discuss a structured maintenance approach' keeps the alliance without endorsing it.
Deal with the real barrier. Ask what specifically worries them - school, basketball, social eating, cost, the tube. Offer concrete supports: a 504-plan letter for school, a sports clearance note, a letter for insurance prior authorization of formula, and a named contact for the first two difficult weeks.
Ethics and scope. Consent must be informed: state the alternatives (steroids, biologics) and the consequence of an abandoned EEN trial. Do not overpromise, do not disparage the gastroenterologist's steroid offer, and document the discussion and the family's decision.